Kornimate/medical-research-clean huggingface dataset:
the context of gambling treatment: towards creating an online service to reduce problem gambling - part five

Conditions: Problem Gambling

Summary: this application involves a multi-stage study with the ultimate goal of developing an online treatment service for problem gamblers. we will recruit up to 100 problem gamblers, and offer problem gambling treatment services to them entirely over the internet. the program will be evaluated based on uptake, experience of the participants, and pre-test vs post-test differences in gambling and well-being.

disordered gambling is now recognized as a behavioral addiction. although the physical consequences of the disorder are very mild, the financial and emotional costs can be enormous. this application involves a multi-stage study with the ultimate goal of developing an online treatment service for problem gamblers. this project was originally designed to take place over a three-year period but has been condensed into two. part one was scoping review. part two involved focus groups with service providers and people experiencing gambling problems. part three will gather some general population information on two on going population survey's run by our research team. part four involved key informant interviews, and part five would be the development and evaluation of a pilot online treatment service. this application deals with part five of the overall project, parts two and four were conducted as 025-2017. in this study, we will recruit up to 100 problem gamblers, and offer problem gambling treatment services to them entirely over the internet. the program will be evaluated based on uptake, experience of the participants, and pre-test vs post-test differences in gambling and well-being. the data reported here are related to part 5 only. due to funding cuts, we were only able to include 2 people in the completed study.

Eligibility criteria:
inclusion criteria: * problem gamblers seeking treatment who are 18 years and older must be willing to have therapy conducted online must have access to a computer and internet be able to communicate in english. exclusion criteria: * not able to communicate in english, has current suicidal ideation, acute psychotic symptoms, current involvement in other gambling treatment, has severe substance abuse problem or complex mental health problems (as assessed by screening tools)
effect of agonist glp1 on adipose tissue in patients undergoing bariatric surgery

Conditions: Obesity

Summary: normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. to this end, the investigators will first study the impact of glp-1 analogues on adipose tissue. the main objective is to show that subjects treated with a glp-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a glp-1 agonist.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age. * patient able to read and understand the information/consent leaflet. * patient with bmi \> 35 with at least one comorbidity. or bmi \> 40 * indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the cpam. * membership of a social security scheme * patient's signed informed consent * for subjects in the glp-1 analogue group: glp-1 analogue taken for at least 3 months. * for non-glp-1 analogue group: never taken glp-1 analogues. exclusion criteria: * pregnant or breast-feeding women. * vulnerable patients (under guardianship) * patients deprived of liberty
a study in previously untreated chronic lymphocytic leukemia (cll) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)

Summary: this is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (cll)/ small lymphocytic lymphoma (sll), excluding those with the 17p deletion, to evaluate a debulking strategy that would enable all participants to receive subsequent venetoclax as outpatients, with lower risk of tumor lysis syndrome.

safety and efficacy data through 13 october 2021 are included in the interim analysis, which was conducted after all participants completed the post-treatment week 65 visit or discontinued from the study.

Eligibility criteria:
inclusion criteria: * adequate hematology, kidney and liver function as described in the protocol * diagnosis of previously untreated chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll) according to 2008 modified international workshop on chronic lymphocytic leukemia national cancer institute-sponsored working group (iwcll nci-wg) criteria * eastern cooperative oncology group (ecog) performance score of 0 - 1 * cll/sll requires treatment according to the iwcll criteria * medium tumor burden (any lymph node \[ln\] 5 to \< 10 cm or absolute lymphocyte count \[alc\] ≥ 25 × 10\^9/l) or high tumor burden (any ln ≥ 10 cm or alc ≥ 25 × 10\^9/l and ln ≥ 5 cm) exclusion criteria: * presence of 17p deletion at screening * richter's syndrome (transformation of cll/sll to aggressive non-hodgkin's lymphoma or hodgkin's lymphoma) * prolymphocytic leukemia

Keywords: cancer chronic lymphocytic leukemia 17p deletion debulking obinutuzumab bendamustine tumor lysis syndrome venetoclax small lymphocytic lymphoma
actions - aortic counterpulsation to improve outcomes in noncardiac surgery

Conditions: Patients With History of Ischemic Heart Disease With LV Dysfunction Undergoing Noncardiac Surgery

Summary: the use of the iabp, in addition to standard care, in high-risk cardiac patients undergoing major noncardiac surgery is feasible and may result in improved perioperative outcomes at 30 days compared with standard care alone, while maintaining acceptable safety with respect to vascular accesss-related complications.


Eligibility criteria:
inclusion criteria: * patients \> 18 years with planned elective major abdominal, noncardiac thoracic, head and neck, vascular, or orthopedic surgery and guideline-treated iscehmic heart disease with left ventricular dysfunction (systolic ejection fraction \< or = 30%) exclusion criteria: * unstable coronary syndromes decompensated or nyha class iv heart failure hemodynamic instability cardiac biomarker instability need for surgical procedure interfering with placement of iabp cardiogenic shock septic shock contraindication to iabp use clinical need for iabp asa score \> or = 5 pregnancy inability to provide informed consent
the factors predicting change of peritoneal transport characters in peritoneal dialysate

Conditions: Peritoneal Fibrosis

Summary: peritoneal fibrosis (pf) is one of the most serious complications after long-term continuous ambulatory peritoneal dialysis (capd). human peritoneal fibroblast (hpfb) and extracellular matrix (ecm) deposition is the most possible causes leading to pf. ecm are mainly synthesized from hpfb and human peritoneal mesothelial cells (hpmc). in the pf process, there is decrement in the quantity of hpmc, loss of permeability for lower molecules, and eventually ultrafiltration failure. this phenomena will result in technique failure. high glucose content of the dialysate and peritonitis have been claimed as major stimulants to the development of pf. in each episode of peritonitis, the number of hpmc will decrease. on the other hand, ecm production will be reinforced by the inflammatory cytokines secreted by the white cells or hpmc per se. high glucose dialysate will induce the above process with more chronic stimulation, and pf followed by technique failure is inevitable. peritoneal fibrosis is definitively diagnosed with peritoneal biopsy, but this is inconvenient for most patients. besides, pathology changes will be noted only after a substantial loss of peritoneal function. the peritoneal equilibration test (pet) is usually used as the index of peritoneal function. however, in the chronic process, pet change is also slow and is unable to be a parameter for treatment outcome. in this study, the factors predicting pet change will be searched, and they could be an index for evaluation and even a marker of preventing or treating pf. in this project, peritoneal dialysis (pd) dialysate will be collected during an annual pet in each pd patient in the national taiwan university hospital (ntuh). some cytokines that will be measured include vasculoendothelial growth factor, hyaluronan, transforming growth factor-β, procollagen, and cancer antigen-125. the same test and measurement will be performed during pet in the next year. the factors which affect pet results will be analyzed such as cytokines, glucose exposure, peritonitis incidence, pd duration, gender, age. the investigators will try to find a convenient acute reactive marker for preventing or treating pf to monitor the pet change clinically.


Eligibility criteria:
inclusion criteria: * all pd patients exclusion criteria: * peritonitis

Keywords: peritoneal dialysis
follow-up of pulmonary radiotoxicity for bronchopulmonary cancer.

Conditions: Cancer, Lung; Radiotherapy; Complications

Summary: assess the consequences of low doses of radiation delivered by the volumetric radiotherapy, on the respiratory capacity of patients treated for bronchopulmonary carcinoma, by a follow up of functional respiratory exploration.

radiation therapy with or without chemotherapy is a stable treatment in the management of patients with localized smack cell bronchopulmonary cancers, or not to small cells not metastatic but not operable. radiation therapy results in changes in respiratory function, as measured by respiratory function tests and represented primarily by spirometry, total body plethysmography, and the diffusion capacity of the alveolar-capillary membrane. although these tests are minimally invasive, few studies have investigated the implications of radiation therapy on lung function in patients treated for pulmonary neoplasia, while these patients are often already carriers of respiratory diseases and will receive further chemotherapy during their illness, subject to their general good condition, including respiratory. no method has been recognized as superior for measuring the consequences of radiation therapy on respiratory function. after chest radiotherapy alone, the decline in diffusion capacity is estimated at 10-34%. new irradiation techniques have emerged over the last decade, in particular dynamic arc therapy. this innovative technology, combined with image-guided irradiation processes, ensures high-precision, short-term treatment, but exposes virtually all of the lungs to irradiation, although at very low doses, the objective consequences of which on respiratory functional explorations have never been reported. the aim of this study is therefore to assess the consequences of low doses of radiation delivered by this recent technology, volumetric therapy, on the respiratory capacity of patients treated with radiotherapy within the framework of of bronchopulmonary carcinoma.

Eligibility criteria:
inclusion criteria: * age \>18 years * bronchopulmonary carcinoma histological proved * oms 0-2 * indication of radio(chimio)therapy alone approved by multidisciplinary comitee * non opposition formular completed exclusion criteria: * sbrt indication * history of thoracic surgery or irradiation * unstable disease * oxygenotherapy dependance * severe chronic bronchitis * collagen disease * pregnancy * contraception refusal * refusal or incapacity to participate
efficacy and tolerance of honey-impregnated dressings in the local management of pressure ulcers

Conditions: Pressure Ulcer

Summary: the main objective of this study is to document the effectiveness of a honey-based medical device (hyalumel) in the management of pressure ulcers. the effectiveness of the medical device will be judged according to the evolution of the surface of the wound at the end of 12 weeks of treatment.

the secondary objectives of this study are to compare the following items between the two arms of the study: a. the evolution of skin microbiota in the wound b. the evolution of the surface and the depth of the wound during follow-up c. the healing process d. patient and caretaker acceptability

Eligibility criteria:
inclusion criteria: * information provided on the implementation of the study, its objectives, constraints and patient rights * the patient, or his/her legal guardian, must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 12 weeks of follow-up * presence of one or more pressure ulcers at stages 2, 3 or 4 according to the european pressure ulcer advisory panel - national pressure ulcer advisory panel (epuap-npuap) classification * wound whose surface is between 1 cm\^2 and 15 cm\^2 * wound present for more than 6 weeks * patient whose wound requires a modern dressing (that is to say, a bandage that is neither tulle nor gauze) without bactericidal agents or antibiotics * no antibiotics for at least 7 days prior to inclusion (after inclusion, the patient can be treated with antibiotics if necessary, regardless of the indications) exclusion criteria: * patient participating in or having participated in another interventional study in the previous 3 months or currently in a patient exclusion period determined by a previous study. * patient under judicial protection * failure to correctly inform the patient or his/her legal representative * patient (or his/her legal guardian) refusal to sign the consent * the patient is pregnant, parturient, or breastfeeding * contraindications (or incompatible combination therapy) for a necessary treatment in this study * patient with an allergy to honey or propolis * the patient's general condition suggests study exclusion before twelve weeks of follow-up * antibiotics received within 7 days prior to inclusion * active neoplastic lesion treated with radiation or chemotherapy * immunosuppressive therapy or other treatment which, in the judgment of the investigator, may interfere with the healing process * surgery planned within twelve weeks of inclusion * stage 1 wound according to the epuap-npuap classification * amputation wound * wound related to a surgical treatment or for which an act of revascularization is envisaged within twelve weeks of inclusion * malignant wound
effects of sustained natural apophyseal glides versus cervical manipulation on pain and disability in wrestle

Conditions: Neck Pain; Disability Physical

Summary: this study will be conducted to evaluate effect of sustained natural apophyseal glides and cervical manipulation in pain and disability of neck among wrestler players .all subjects will be selected between ages 18 to 35 years. data will be collected from players in registered gujranwala wrestling clubs. study design will be randomized clinical trial. neck pain disability index questionnaire and nprs will be used to check the disability in neck and intensity of pain respectively. informed consent will be taken from all participants. study will be conducted in 6 weeks' time period. data will be collected at the start of research and after six week post research date will collected for analysis. patients will be allocated randomly into two main groups. group a is the interventional group and group b is the control group. on group a snag will be performed and group b will be provided by cervical manipulation to compare the effects of both techniques. spss will be used for data entry and analysis.

the main aim of the study is to compare the effects of sustained natural apophyseal glides versus cervical manipulation on pain and disability in nonspecific acute neck pain among wrestlers. acute neck pain and disabilities are most common among wrestlers. different studies occur on snags and mobilizations on various athletes but there is a literature gap between comparison of snags and cervical manipulation in neck disabilities. this study will be conducted to evaluate effect of sustained natural apophyseal glides and cervical manipulation in pain and disability of neck among wrestler players .all subjects will be selected between ages 18 to 35 years. data will be collected from players in registered gujranwala wrestling clubs. study design will be randomized clinical trial. neck pain disability index questionnaire and nprs will be used to check the disability in neck and intensity of pain respectively. informed consent will be taken from all participants. study will be conducted in 6 weeks' time period. data will be collected at the start of research and after six week post research date will collected for analysis. patients will be allocated randomly into two main groups. group a is the interventional group and group b is the control group. on group a snag will be performed and group b will be provided by cervical manipulation to compare the effects of both techniques. spss will be used for data entry and analysis.

Eligibility criteria:
inclusion criteria: * 18 to 35 years male only * acute non-specific neck pain exclusion criteria: * patients with history of discogenic cause in neck. * history of postoperative patients * individuals who was not willing and individuals with systemic disorders * any musculoskeletal(msk) injury that effect their performance like fracture and bruises etc.

Keywords: pain neck injury snags cervical manipulation disability
rhgh and rhigf-1 combination therapy in children with short stature associated with igf-1 deficiency

Conditions: Insulin-like Growth Factor-1 Deficiency

Summary: igf-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. growth hormone is produced by a small gland at the base of the brain (the pituitary). together igf-1 and gh are large contributors to growth during infancy, childhood, and adolescence. children with igf deficiency are short and have an imbalance in the levels of growth hormone and igf-1 that their body produces. their growth hormone levels are normal or even high, but igf-1 levels do not increase normally in response to growth hormone. as a result, they have a type of growth hormone insensitivity and an inability to grow normally. this study is a test to see whether daily dosing with a combination of rhigf-1 and rhgh will help children with igfd grow taller more quickly than children treated with rhgh alone. the study medications, rhigf-1 and rhgh, are approved by the us food and drug administration (fda) for use in some growth disorders in children, but the combination of rhigf-1 and rhgh in children with igf-1 deficiency (igfd) is investigational.


Eligibility criteria:
inclusion criteria: * parents or legally authorized representatives must give signed informed consent before any trial-related activities * igf-1 sds of ≤ -1 for age and gender * short stature, as defined by a height sds of ≤ -2 for age and gender * chronological age ≥ 5 years * bone age ≤ 11 years in boys and ≤ 9 years in girls * gh sufficiency, defined as a maximal stimulated gh response of greater than or equal to 10 ng/ml at visit 2 (note: upon approval of the medical monitor, the result of a prior gh stimulation test may satisfy this requirement). * prepubertal status * adequate nutrition as evidenced by a body mass index (bmi) greater than or equal to the 5th percentile for age and gender exclusion criteria: * severe primary igfd (defined as height and igf-1 sds ≤ 3, and stimulated gh response greater than or equal to 10 ng/ml) * prior or current use of medications with the potential to alter growth patterns including gh, igf-1, igfbp-3, gonadotrophin agonists (e.g., lupron), aromatase inhibitors, androgens and estrogens * known or suspected allergy to rhgh, rhigf-1 or a constituent of their formulations * current use of medications for attention deficit disorder * a chronic health condition that requires anti-inflammatory steroids or daily medication unless approved by the medical monitor

Keywords: igf-1 deficiency growth iss constitutional growth delay primary igfd primary igf deficiency
effects of aliskiren, ramipril, and the combination on levels of angiotensin ii in patients with decompensated systolic heart failure

Conditions: Heart Failure

Summary: in addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called raas (renin-angiotensin-aldosterone system) at the tissue level. an increase of angiotensin ii is associated with progression of heart failure. although the use of ace-inhibitors in heart failure shows clinical benefit, an increase in angiotensin ii due to an angiotensin ii "escape" phenomenon is not desirable. it is not yet known if a direct renin inhibitor can reduce or even prevent the angiotensin ii escape phenomenon associated with the use of an ace-inhibitor. therefore the study tested the effects of ramipril, aliskiren and the combination of both on levels of angiotensin ii in the blood in patients with systolic heart failure


Eligibility criteria:
inclusion criteria: * decompensated systolic heart failure, left ventricular ejection fraction ≤40% * brain natriuretic peptide (bnp) level ≥ 100 pg/ml exclusion criteria: * use of angiotensin converting enzyme(ace) or angiotensin receptor blocker (arb) inhibitor treatment following the run-in period or requirement of both treatments * acute heart failure secondary to acute myocardial infarction, acute coronary syndrome or new tachyarrhythmia * occurrence of unstable angina or myocardial infarction within 12 weeks prior to screening * history of cardiomyopathy such as postpartum, restrictive, infective, hypertrophic obstructive * history of right heart failure due to pulmonary disease * history of untreated second or third degree atrioventricular heart block other protocol-defined inclusion/exclusion criteria applied

Keywords: heart failure systolic aliskiren ramipril angiotensin ii ang ii plasma renin activity pra plasma renin concentration pr, brain natriuretic peptide bnp urinary aldosterone escape pharmacokinetic pk
predictors of survival of dkd patients in assiut university hospital

Conditions: Chronic Kidney Disease(CKD)

Summary: in recent years, the global prevalence of diabetes has risen significantly. according to the 9th edition of the international diabetes federation atlas, an estimated 463 million adults were living with diabetes in 2019, representing approximately 9.3% of the population, with an average annual increase of 51%. diabetes is associated with multiple complications that can significantly impact patient outcomes . in 2019 alone, around 4.2 million deaths were attributed to diabetes and its complications, accounting for approximately 11.3% of all global deaths . in diabetic patients, several factors influence renal survival, including glycemic control, blood pressure management, lifestyle interventions, and pharmacological therapies such as renin-angiotensin-aldosterone system (raas) inhibitors, sodium-glucose co-transporter-2 (sglt2) inhibitors, and glucagon-like peptide-1 (glp-1) receptor agonists(9). early detection of kidney dysfunction through biomarkers like estimated glomerular filtration rate (egfr) and urinary albumin-to-creatinine ratio (uacr) plays a pivotal role in improving renal outcomes. this study aims to evaluate the factors affecting patients survival in diabetic patients, identify early predictors of renal function decline, and assess the effectiveness of current therapeutic strategies.


Eligibility criteria:
inclusion criteria: * ● patients age \> 18 years old * both sex * diabetic patients with hba1c level \>6.5( type 1 and 2) * diabetic patients with ckd 4, 5 ) * hd pt exclusion criteria: * ● chronic kidney diseases stage 1,2, and 3. * acute kidney injury. * patients with any other causes of ckd autoimmune disease

Keywords: diabetic nephropathy